In summary, this study delineates a previously unrecognized mechanism underpinning c-Met-PLXDC2–mediated radioresistance, opening the door for considering possible combinatorial approaches of c-Met inhibitors with radiotherapy in HNSCC. The gene discussed is PLXDC2; the disease is head and neck squamous cell carcinoma.